

Serwaa Akoto Bawua, Kiyoshi Ichihara\*, Rosemary Keatley, John Arko-Mensah, Patrick F. Ayeh-Kumi, Rajiv Erasmus and Julius Fobil

# Derivation of sex and age-specific reference intervals for clinical chemistry analytes in healthy Ghanaian adults

<https://doi.org/10.1515/cclm-2022-0293>

Received March 25, 2022; accepted June 13, 2022;

published online July 4, 2022

## Abstract

**Objectives:** This study is aimed at establishing reference intervals (RIs) of 40 chemistry and immunochemistry analytes for Ghanaian adults based on internationally harmonized protocol by IFCC Committee on Reference Intervals and Decision Limits (C-RIDL).

**Methods:** A total of 501 healthy volunteers aged  $\geq 18$  years were recruited from the northern and southern regions of Ghana. Blood samples were analyzed with Beckman-Coulter AU480 and Centaur-XP/Siemen auto-analyzers. Sources of variations of reference values (RVs) were evaluated by multiple regression analysis (MRA). The need for partitioning RVs by sex and age was guided by the SD ratio (SDR). The RI for each analyte was derived using parametric method with application of the latent abnormal values exclusion (LAVE) method.

**Results:** Using  $\text{SDR} \geq 0.4$  as threshold, RVs were partitioned by sex for most enzymes, creatinine, uric acid (UA), bilirubin, immunoglobulin-M. MRA revealed age and body mass index (BMI) as major source of variations of many analytes. LAVE lowered the upper limits of RIs for alanine/aspartate aminotransferase,  $\gamma$ -glutamyl transaminase and lipids. Exclusion of individuals with  $\text{BMI} \geq 30$  further

lowered the RIs for lipids and CRP. After standardization based on value-assigned serum panel provided by C-RIDL, Ghanaian RIs were found higher for creatine kinase, amylase, and lower for albumin and urea compared to other collaborating countries.

**Conclusions:** The LAVE effect on many clinical chemistry RIs supports the need for the secondary exclusion for reliable derivation of RIs. The differences in Ghanaian RIs compared to other countries underscore the importance of country specific-RIs for improved clinical decision making.

**Keywords:** between-country differences; bias ratio; ethnicity; latent abnormal values exclusion method; multiple regression analysis; nonparametric method; parametric method; standard deviation ratio; standardization.

**Abbreviations:** Alb, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMY, amylase; AG, anion gap; AST, aspartate aminotransferase; BD, Becton Dickinson; BMI, body mass index; BR, bias ratio; Ca, calcium; CK, creatine kinase; Cl, chloride; C3, complement component 3; C4, complement component 4; CDL, clinical decision limit; CI, confidence interval; Cre, creatinine; C-RIDL, Committee on Reference Intervals and Decision Limits; CRP, C-reactive protein; CV(b), CV of the regression slope b; DBil, direct bilirubin; eGFR, estimated glomerular filtration rate; F, female; GGT, gamma-glutamyl transferase; Glb, globulin; Glu, glucose;  $\text{HbA}_{1c}$ , hemoglobin  $\text{A}_{1c}$ ; HDL-C, high-density lipoprotein cholesterol; IFCC, International Federation of Clinical Chemistry and Laboratory Medicine; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; IP, inorganic phosphate; K, potassium; LAVE, latent abnormal values exclusion; LDH, lactate dehydrogenase; LDL-C, low-density lipoprotein cholesterol; LL, lower limit; M, male; MF, male + female; Mg, magnesium; MRA, multiple regression analysis; Na, sodium; NP, non-parametric; P, parametric; RI, reference interval;  $r_p$ , standardized partial correlation coefficient; RV, reference values; SDR, standard deviation ratio; SV, sources of variation; TBil, total bilirubin; TG, triglycerides; TC, total cholesterol;  $\text{TCO}_2$ , total carbon dioxide; TP, total protein; UA, uric acid; UL, upper limit.

\*Corresponding author: Kiyoshi Ichihara, MD, PhD, Department of Clinical Laboratory Sciences, Faculty of Health Sciences, Yamaguchi University Graduate School of Medicine, Minami-Kogushi 1-1-1, Ube, 755-8505, Japan, Phone: +81-90-7895-0432, Fax: +81-836-35-5213, E-mail: [ichihara@yamaguchi-u.ac.jp](mailto:ichihara@yamaguchi-u.ac.jp). <https://orcid.org/0000-0002-6039-4537>

Serwaa Akoto Bawua, John Arko-Mensah and Julius Fobil, Department of Biological, Environmental & Occupational Health Sciences, University of Ghana School of Public Health, Accra, Ghana

Rosemary Keatley, Medlab Ghana Ltd., Roman Ridge, Accra, Ghana

Patrick F. Ayeh-Kumi, Department of Microbiology, University of Ghana Medical School, College of Health Sciences, University of Ghana, Korle-Bu, Ghana

Rajiv Erasmus, University of Stellenbosch, Division of Chemical Pathology, Tygerberg, Cape Town, South Africa

## Introduction

Clinical laboratory reference intervals (RI) are supposed to be established and verified in every country. However, few countries carry out their own RI studies due to challenges and cost involved in directly recruiting healthy individuals and deriving RIs based on well-defined procedures [1–3]. Consequently, in Ghana diagnostic laboratories rely on reference intervals provided by the manufacturers of *in vitro* diagnostic instruments. These RIs may have been derived from a population with different characteristics which might not be appropriate. Previous studies have reported regional differences in certain chemistry analytes [4, 5] either due to ethnicity, diet, and environmental conditions. This clearly points to the importance of establishing RIs for local populations. IFCC Committee on Reference Intervals and Decision Limits (C-RIDL) has elaborated a protocol that harmonizes the pre-analytical, analytical and post-analytical study processes, and promotes the common derivation of RIs through standardization and ensures ease of comparison of derived RIs across different regions, countries and ethnicities [6, 7].

Several studies conducted in African populations have reported variations in RIs for some chemistry analytes [8–10]. These observations emphasize the need for establishing RIs specific for the Ghanaian population, acknowledging that most diagnostic laboratories in Ghana adopt RIs from extant literature and manufacturers' inserts [11]. Hence, we conducted a nationwide study to establish standardized RIs for major chemistry analytes by recruiting well-defined healthy Ghanaian adults based on the C-RIDL protocol and value-assigned serum panel [12]. Additional objectives were (1) to evaluate sources of variation of reference values (RVs) specific to each analyte and (2) to explore unique features of Ghanaian/African RIs from an international perspective.

## Materials and methods

### Study population and recruitment

Healthy volunteers were recruited from Accra in the South and Tamale in the North, which represent two different ethnic groups. Recruitment was based on the C-RIDL protocol for harmonized implementation of multicenter studies [7]. A target sample size of 500 was set with equal sex and age (18–70 years) distributions. Through posters and media advertisement, volunteers were recruited from public institutions, health facilities, churches, etc. A questionnaire based on the protocol was administered to record volunteers' health status.

### Inclusion/exclusion criteria

The exclusion criteria by the protocol were individuals with known diabetes mellitus under drug therapy, recent ( $\leq 14$  days) recovery from acute illness, injury, or surgery requiring hospitalization, known carrier state of hepatitis viruses or HIV, pregnancy or within one year after childbirth. Additionally, we excluded individuals with body mass index (BMI)  $> 35$  kg/m<sup>2</sup>, alcohol consumption  $\geq 70$  g/day, smoking habit of  $> 20$  cigarettes/day, under regular medication. Upon completion of the questionnaire, the eligible volunteers from Accra were scheduled for blood collection at Medlab Ghana, while specimens taken in Tamale were transported to Medlab Ghana in Accra within 6 h each day. Participants' results were reported individually upon completion of measurements.

### Laboratory analysis

**Blood sampling and storage:** Blood sample collection was done in two stages, the first from participants residing in the southern Ghana (Accra), and the second from the northern part (Tamale). The sample collection lasted for 6 months (June through December 2017). Blood was drawn under basal conditions as recommended in the protocol between 7:00 and 10:00AM after overnight fasting, and avoidance of strenuous muscular exertion (for three days) or night shift work prior to the sampling. Sitting posture of 20–30 min before venipuncture was requested to avoid postural changes in test results [13]. Thirty mL of blood was drawn into three evacuated serum separator tubes (BD-Vacutainer, West Africa), one sodium fluoride tube for glucose, and one vacutainer tube containing K<sub>2</sub>-EDTA for HbA<sub>1c</sub>. Anthropometric measurements which included weight, height, body mass index (BMI), waist circumference and blood pressure were taken on the day of sampling.

The blood was centrifuged at 1,200g for 10 min at room temperature and all the serum specimens were divided into five aliquots of 2 mL well-sealed freezing tubes (ThermoFisher, West Africa), and was immediately stored at  $-80$  °C until the time of collective measurements. Also, some samples were preserved with dry ice at  $-80$  °C and transported to the referral laboratory at SynLab, Germany for the analysis of tumour markers, thyroid test and immunological analytes. Sample analysis were performed from January 15th through February 13th, 2018. The purpose for preparing multiple serum aliquots was our plan of testing additional analytes by immunoassay, and for storage in anticipation of future testing of new markers.

### Target analytes and measurements

The 34 analytes measured in serum were ALP, GGT, AST, ALT, LDH, CK, amylase (AMY), triglycerides (TG), total cholesterol (TC), HDL-C, LDL-C, Na, K, Cl, Ca, inorganic phosphate (IP), Mg, total CO<sub>2</sub> (TCO<sub>2</sub>), anion gap (AG), total protein (TP), albumin (Alb), total bilirubin (TBil), direct bilirubin (DBil), urea, creatinine (Cre), uric acid (UA), glucose (Glu), HbA<sub>1c</sub>, CRP, complement component 3 and 4 (C3, C4), IgA, IgG and IgM. Six calculated parameters were globulin (Glb=TP – Alb), adjusted-Ca ( $aCa = Ca - 0.025 \times [Alb - 40]$ ), eGFR (CKD-EPI) [14], TC/HDL, HDL/LDL and non-HDL cholesterol ( $nonHDL = TC - HDL - C$ ).

Chemistry analytes were measured in batches on AU480 auto-analyzer (Beckman-Coulter, US). While inflammatory markers were measured by immunoturbidometric assays using Centaur-XP auto-

analyzer (Siemens, Germany). HbA<sub>1c</sub> was measured by Beckman Coulter AU 460 using the latex agglutination inhibition method. Detailed analytical methods and precisions are summarized in Supplementary Table 1.

## Quality control

All measurements were carried out in Medlab Ghana and SynLab, Germany, all ISO15189 accredited Medical Laboratories, according to the laboratories' SOPs and Quality Manual to ensure reliable measurements. Additionally, a mini-panel of sera were prepared from healthy volunteers and measured each day in singleton to monitor the stability of the assay according to the protocol [7, 12].

## Standardization based on value-assigned serum panel

Participating laboratories to the C-RIDL global study received a panel of 50 sera that had assigned values for 30 chemistry analytes [12]. The sera were measured to enable recalibration of reference values (RVs), where necessary. The test results also allowed for direct comparison of RVs among collaborating laboratories.

## Ethical approval

The study protocol conforming to the Declaration of Helsinki was approved by the Ethical Review Committee of the College of Health Sciences, University of Ghana (CHS-Et/M.8-P4.14/2016–2017). Written consents were obtained from all volunteers. Participants' confidentiality was maintained at all times.

## Statistical analyses

**Sources of variation of RVs:** Multiple regression analysis (MRA) was performed separately for each sex by setting RVs of each analyte as an objective variable. As explanatory variables, the following six factors were set: age, BMI, ethnicity (Akan=1; non-Akan=0), hours of standing/day (HrStand), habit of drinking alcohol (Yes=1; No=0), days/week of regular exercise (ExerLvl: 0–7). RVs of analytes that showed skewed distributions were transformed logarithmically (TBil, DBil, TG, ALT, AST, GGT, CK, CRP) or by square-root (LDH, ALP, AMY, IgA, IgM) to reduce the skewness. The association of each explanatory variable with the objective variable was expressed as standardized partial regression coefficient ( $r_p$ ), which takes a value between –1.0 and 1.0. We regarded  $|r_p| \geq 0.2$  as an appreciable effect size of correlation, which is between 'small' (0.1) and 'medium' (0.3) levels proposed by Cohen [15].

**Partitioning criteria of RVs:** The need for partitioning RVs by sex and age was guided by computing standard deviation ratio (SDR) [6]. The SDR represents a ratio of between-subgroup SD (variation of subgroup means from the grand mean) to between-individual SD (approximately 1/4 the RI width, representing between-individual SD). Two-level nested ANOVA was performed to compute between-sex SD and between-age SD after partitioning age at 30, 40, and 50 years. The SDR for between-sex SD ( $SDR_{sex}$ ), and for between-age SD ( $SDR_{age}$ ) were computed as a ratio to the residual SD (or between-individual SD). Since between-age variation changes by sex, we also computed  $SDR_{age}$

for each sex by one-way ANOVA.  $SDR \geq 0.40$  was considered as practically significant between-subgroup difference to derive sex or age specific RIs [5].

However, SDR is sometimes insensitive to actual difference (bias) at lower or upper limit of the RI (LL, UL) after partitioning because SDR represents central tendency of between-group differences, not necessarily represents differences at LL or UL. Therefore, we set up a secondary criterion called bias ratio (BR) at LL or UL,  $BR_{LL}$  or  $BR_{UL}$ , as described elsewhere [16, 17].

$$BR_{LL} = \frac{|LL_M - LL_F|}{(UL_{MF} - LL_{MF})/3.92}, \quad BR_{UL} = \frac{|UL_M - UL_F|}{(UL_{MF} - LL_{MF})/3.92}$$

where subscript M, F, and MF represent male, female, and male + female, respectively.

As a threshold of BR, 0.375 was used in previous studies [16, 17] following the specification of allowable analytical bias [16] at a minimum level. We adopted it in judging a bias at LL or UL before and after standardization or with/without LAVE procedure (see below). Whereas the threshold of 0.375 was found too sensitive when used in judging the need for partitioning by sex or age, hence we adopted 0.57 for the purpose (from relationship of bias ( $\Delta$ ) and SD: see Discussion). However, if actual between-group difference at LL or UL was too small from clinical perspective, partition was withheld.

**Derivation of reference intervals:** Parametric and non-parametric methods were used in deriving the RIs. For the parametric method, RVs were first transformed into Gaussian distribution using two parameter Box-Cox power transformation formula [6, 17], and the central 95% range was calculated as mean  $\pm$  1.96SD (after truncating values outside mean  $\pm$  2.81SD once). Then, the range was reverse transformed to get LL and UL in the original scale. The 90% confidence intervals (CIs) for LL and UL were estimated using the bootstrap method through iterative resampling of 50 times.

In calculating the RIs, to reduce the influence of inappropriate values attributable to latent diseases or noncompliance to the sampling requirements, the latent abnormal values exclusion (LAVE) method was used. It is an iterative RI optimization procedure [6, 17] with initial calculation of RIs done analyte by analyte independently. In the subsequent iterative calculation, individuals were excluded who had two or more results outside the RIs derived in the previous computation among mutually associated reference tests, which represent nutritional, inflammatory conditions or muscular damage: Alb, Glb, UA, Glu, AST, GGT, CK, LDH, TC, nonHDL, TG, and CRP.

# Results

## Demographic profiles of participants (Table 1)

The total sample size of reference individuals included in data analyses was 501, comprising 54% (n=270) males and 46% (n=231) females. The mean age and SD was  $41.3 \pm 13.5$  years with almost flat distribution. The volunteers were from Accra (77%) and Tamale (23%). Regarding ethnicity, the participants were grouped into Akan and non-Akan based on their common language and diet. The Akan constituted

40.3% (n=202) and non-Akans 59.7% (n=299). Mean  $\pm$  SD of BMI was  $24.9 \pm 3.5$ (M),  $26.9 \pm 4.0$ (F) kg/m<sup>2</sup>, systolic/diastolic blood pressures were  $121.2 \pm 11.5/78.9 \pm 7.2$  mmHg. Almost all participants (99.4%) recruited were non-smokers, which is the cultural norm in Ghana. It is notable that individuals with any allergy, such as allergic rhinitis or atopic dermatitis, was as low as 1.9% in males and 0.4% in females. In relation to the testing of HbA<sub>1c</sub>, we retrospectively ascertained the lack of disorders that may have affected its value, such as severe iron deficiency anemia, based on our previous report of hematology RI study [18]. While possible influence of sickle cell anemia in adults in calculating the RI was unlikely judged from its new-born incidence in Ghana of 2% [19].

## Sources of variation analysis by MRA

The results of MRA performed for exploration of sources of variation (SVs) of each analyte are summarized in Table 2. By setting  $|r_p| > 0.2$  as the threshold, age and BMI were

the key factors associated with many of the analytes. The notable age-related changes were mostly found in females for Na, urea, TCO<sub>2</sub>, Cre, TG, UA, Mg, ALP, and TC in the descending order of strength, and only for TCO<sub>2</sub> and IgA in males. While, age-related decrease ( $r_p < -0.2$ ) was observed in IgM, TP, and Glb in female, and Alb, TP, and Ca in males. Since there is no association of age in adjusted Ca (aCa), the decrease in Ca is obviously confounded by age-related decrease in Alb. These age-related changes are shown for BMI and RVs of eight representative analytes in Figure 1.

With respect to BMI-related changes, analytes tested in males showed generally higher associations with BMI compared to females. Positive association of RVs with BMI ( $r_p > 0.2$ ) were found in males for C3, TC/HDL, UA, nonHDL, ALT, GGT, LDL-C, TC, TG, Glu, HbA<sub>1c</sub>, in the descending order of influence; while, in females for C3, CRP, ALT, TG, TC/HDL, UA, nonHDL, HbA<sub>1c</sub>, LDL-C, and GGT; Conversely, negative association of RVs with BMI ( $r_p < -0.2$ ) were noted for HDL/LDL in both sexes, and HDL-C in males, and AMY in

**Table 1:** Demography of the participants.

|                         |               | Male             | Female           | Sum              |
|-------------------------|---------------|------------------|------------------|------------------|
| Age, years              | n             | 270              | 231              | 501              |
|                         | Mean $\pm$ SD | $40.9 \pm 13.5$  | $41.8 \pm 13.6$  | $41.3 \pm 13.5$  |
| Ethnicity 1             | Akan          | 108 (40.0)       | 94 (40.7)        | 202 (40.3)       |
|                         | Ewe           | 46 (17.0)        | 32 (13.9)        | 78 (15.6)        |
|                         | Ga            | 38 (14.1)        | 29 (12.6)        | 67 (13.4)        |
|                         | Other         | 78 (28.9)        | 76 (32.9)        | 154 (30.7)       |
|                         |               |                  |                  |                  |
| Ethnicity 2             | Akan          | 108 (40.0)       | 94 (40.7)        | 202 (40.3)       |
|                         | Other         | 162 (60.0)       | 137 (59.3)       | 299 (59.7)       |
| Waist circumference, cm | n             | 270              | 231              | 501              |
|                         | Mean $\pm$ SD | $34.59 \pm 3.56$ | $36.02 \pm 4.56$ | $35.25 \pm 4.11$ |
| BMI, kg/m <sup>2</sup>  | n             | 270              | 231              | 501              |
|                         | Mean $\pm$ SD | $24.86 \pm 3.54$ | $26.93 \pm 4.03$ | $25.81 \pm 3.91$ |
| SBP, mmHg               | n             | 270              | 231              | 501              |
|                         | Mean $\pm$ SD | $122.6 \pm 10.9$ | $119.6 \pm 12.0$ | $121.2 \pm 11.5$ |
| DBP, mmHg               | n             | 270              | 231              | 501              |
|                         | Mean $\pm$ SD | $78.8 \pm 7.0$   | $79.0 \pm 7.4$   | $78.9 \pm 7.2$   |
| Allergy                 | Yes           | 5 (1.9)          | 1 (0.4)          | 6 (1.2)          |
|                         | No            | 265 (98.1)       | 230 (99.6)       | 495 (98.8)       |
| Alcohol                 | Yes           | 42 (15.6)        | 24 (10.4)        | 66 (13.2)        |
|                         | No            | 228 (84.4)       | 207 (89.6)       | 435 (86.8)       |
| Regular exercise        | Yes           | 121 (45.0)       | 85 (36.8)        | 206 (41.2)       |
|                         | No            | 148 (55.0)       | 146 (63.2)       | 294 (58.8)       |
| Hour stand per day      | n             | 270              | 229              | 499              |
|                         | Mean $\pm$ SD | $3.5 \pm 2.1$    | $3.4 \pm 2.0$    | $3.5 \pm 2.0$    |
| Hour sit per day        | n             | 270              | 231              | 501              |
|                         | Mean $\pm$ SD | $4.94 \pm 2.10$  | $4.73 \pm 1.92$  | $4.84 \pm 2.02$  |
| Hour sleep per day      | n             | 270              | 231              | 501              |
|                         | Mean $\pm$ SD | $6.5 \pm 1.1$    | $6.5 \pm 1.2$    | $6.5 \pm 1.2$    |
| Hour outdoor per day    | n             | 269              | 230              | 499              |
|                         | Mean $\pm$ SD | $3.5 \pm 2.7$    | $2.9 \pm 2.4$    | $3.2 \pm 2.5$    |



Table 2: Multiple regression analysis for sources of variation of reference values.

| Male              | n   | R     | Age         | Akan        | BMI         | Alcohol | ExerLvl | HrStand |
|-------------------|-----|-------|-------------|-------------|-------------|---------|---------|---------|
| TP                | 269 | 0.390 | <b>0.35</b> | 0.07        | 0.02        | 0.01    | 0.11    | 0.06    |
| Alb               | 269 | 0.461 | <b>0.42</b> | 0.00        | 0.05        | 0.05    | 0.11    | 0.06    |
| Glb               | 269 | 0.189 | 0.14        | 0.09        | 0.01        | 0.05    | 0.06    | 0.04    |
| TBil              | 268 | 0.201 | 0.07        | 0.10        | 0.02        | 0.13    | 0.07    | 0.07    |
| DBil              | 267 | 0.207 | 0.08        | 0.04        | 0.08        | 0.07    | 0.06    | 0.11    |
| UA                | 266 | 0.399 | 0.04        | 0.01        | <b>0.38</b> | 0.01    | 0.08    | 0.01    |
| Urea              | 269 | 0.208 | 0.04        | 0.07        | 0.06        | 0.09    | 0.15    | 0.04    |
| Cre               | 269 | 0.199 | 0.11        | 0.05        | 0.03        | 0.05    | 0.08    | 0.11    |
| Na                | 268 | 0.335 | 0.15        | 0.17        | 0.05        | 0.19    | 0.04    | 0.01    |
| K                 | 268 | 0.194 | 0.10        | 0.09        | 0.12        | 0.07    | 0.06    | 0.03    |
| Cl                | 269 | 0.221 | 0.13        | 0.07        | 0.11        | 0.02    | 0.06    | 0.10    |
| TCO <sub>2</sub>  | 269 | 0.328 | <b>0.27</b> | 0.11        | 0.04        | 0.16    | 0.02    | 0.10    |
| AG                | 269 | 0.411 | 0.20        | <b>0.24</b> | 0.03        | 0.19    | 0.11    | 0.13    |
| Ca                | 268 | 0.383 | <b>0.34</b> | 0.11        | 0.08        | 0.03    | 0.08    | 0.04    |
| aCa               | 268 | 0.176 | 0.03        | 0.14        | 0.03        | 0.09    | 0.02    | 0.01    |
| Mg                | 269 | 0.200 | 0.12        | 0.12        | 0.08        | 0.01    | 0.01    | 0.08    |
| IP                | 267 | 0.279 | 0.11        | 0.20        | 0.09        | 0.13    | 0.00    | 0.02    |
| AST               | 268 | 0.251 | 0.03        | 0.02        | 0.17        | 0.17    | 0.08    | 0.03    |
| ALT               | 267 | 0.416 | 0.16        | 0.08        | <b>0.33</b> | 0.19    | 0.05    | 0.06    |
| LDH               | 268 | 0.289 | 0.07        | 0.16        | 0.13        | 0.09    | 0.14    | 0.04    |
| ALP               | 268 | 0.109 | 0.04        | 0.08        | 0.01        | 0.05    | 0.03    | 0.03    |
| GGT               | 266 | 0.368 | 0.03        | 0.09        | <b>0.32</b> | 0.14    | 0.06    | 0.06    |
| CK                | 269 | 0.208 | 0.11        | 0.01        | 0.13        | 0.11    | 0.02    | 0.05    |
| AMY               | 268 | 0.185 | 0.02        | 0.04        | 0.18        | 0.01    | 0.02    | 0.04    |
| Glu               | 265 | 0.288 | 0.04        | 0.01        | <b>0.27</b> | 0.06    | 0.04    | 0.04    |
| HbA <sub>1c</sub> | 269 | 0.333 | 0.13        | 0.10        | <b>0.25</b> | 0.01    | 0.06    | 0.04    |
| TC                | 269 | 0.315 | 0.07        | 0.09        | <b>0.28</b> | 0.03    | 0.03    | 0.02    |
| TG                | 269 | 0.433 | 0.17        | 0.03        | <b>0.28</b> | 0.02    | 0.04    | 0.19    |
| HDL-C             | 269 | 0.294 | 0.03        | 0.09        | <b>0.25</b> | 0.00    | 0.02    | 0.10    |
| LDL-C             | 269 | 0.329 | 0.04        | 0.06        | <b>0.31</b> | 0.03    | 0.02    | 0.01    |
| nonHDL            | 269 | 0.382 | 0.07        | 0.07        | <b>0.35</b> | 0.03    | 0.03    | 0.04    |
| TC/HDL            | 269 | 0.449 | 0.04        | 0.02        | <b>0.42</b> | 0.04    | 0.02    | 0.09    |
| HDL/LDL           | 269 | 0.411 | 0.04        | 0.00        | <b>0.39</b> | 0.02    | 0.00    | 0.05    |
| CRP               | 268 | 0.300 | 0.19        | 0.03        | 0.16        | 0.03    | 0.09    | 0.06    |
| IgG               | 268 | 0.168 | 0.06        | 0.04        | 0.08        | 0.11    | 0.01    | 0.01    |
| IgA               | 269 | 0.226 | <b>0.22</b> | 0.01        | 0.00        | 0.05    | 0.01    | 0.02    |
| IgM               | 267 | 0.170 | 0.04        | 0.07        | 0.11        | 0.06    | 0.08    | 0.01    |
| C3                | 269 | 0.515 | 0.01        | 0.00        | <b>0.50</b> | 0.06    | 0.11    | 0.08    |
| C4                | 267 | 0.328 | 0.16        | 0.09        | <b>0.21</b> | 0.12    | 0.08    | 0.05    |

| Females           | n   | R     | Age          | Akan         | BMI          | Alcohol | ExerLvl     | HrStand      |
|-------------------|-----|-------|--------------|--------------|--------------|---------|-------------|--------------|
| TP                | 229 | 0.318 | <b>-0.21</b> | -0.04        | -0.15        | 0.00    | 0.13        | -0.03        |
| Alb               | 229 | 0.273 | -0.04        | -0.07        | -0.17        | -0.01   | <b>0.20</b> | 0.01         |
| Glb               | 229 | 0.255 | <b>-0.22</b> | 0.00         | -0.08        | 0.00    | 0.03        | -0.04        |
| TBil              | 229 | 0.229 | 0.11         | -0.18        | 0.01         | 0.09    | 0.07        | -0.01        |
| DBil              | 229 | 0.218 | 0.08         | -0.18        | -0.04        | 0.11    | 0.07        | 0.03         |
| UA                | 229 | 0.420 | <b>0.27</b>  | 0.06         | <b>0.25</b>  | 0.00    | -0.06       | -0.04        |
| Urea              | 229 | 0.408 | <b>0.37</b>  | -0.02        | 0.03         | 0.11    | 0.13        | -0.05        |
| Cre               | 229 | 0.330 | <b>0.29</b>  | 0.03         | 0.06         | 0.08    | -0.08       | -0.04        |
| Na                | 228 | 0.614 | <b>0.57</b>  | -0.10        | 0.01         | 0.03    | -0.11       | -0.06        |
| K                 | 228 | 0.229 | 0.17         | 0.11         | -0.03        | -0.05   | 0.08        | -0.06        |
| Cl                | 229 | 0.241 | 0.14         | 0.17         | -0.03        | 0.01    | -0.14       | 0.07         |
| TCO <sub>2</sub>  | 229 | 0.449 | <b>0.32</b>  | 0.13         | 0.11         | -0.11   | 0.16        | -0.10        |
| AG                | 229 | 0.345 | 0.06         | <b>-0.30</b> | -0.05        | 0.08    | -0.10       | -0.03        |
| Ca                | 229 | 0.170 | 0.09         | -0.04        | -0.03        | 0.07    | 0.13        | -0.03        |
| aCa               | 228 | 0.224 | 0.15         | 0.00         | 0.11         | 0.10    | -0.01       | -0.05        |
| Mg                | 229 | 0.340 | <b>0.26</b>  | -0.18        | -0.07        | 0.00    | 0.03        | -0.10        |
| IP                | 228 | 0.375 | 0.07         | <b>-0.26</b> | -0.04        | -0.04   | -0.04       | <b>-0.20</b> |
| AST               | 229 | 0.164 | 0.05         | 0.01         | 0.06         | -0.07   | -0.09       | -0.04        |
| ALT               | 228 | 0.312 | -0.10        | 0.03         | <b>0.29</b>  | -0.04   | 0.10        | 0.03         |
| LDH               | 229 | 0.250 | 0.08         | -0.18        | 0.11         | 0.07    | 0.01        | -0.07        |
| ALP               | 228 | 0.300 | <b>0.23</b>  | -0.09        | 0.09         | -0.05   | -0.02       | -0.01        |
| GGT               | 229 | 0.269 | 0.08         | 0.00         | <b>0.21</b>  | 0.08    | -0.01       | 0.10         |
| CK                | 227 | 0.237 | 0.07         | 0.05         | 0.17         | -0.04   | 0.10        | 0.03         |
| AMY               | 227 | 0.342 | -0.03        | 0.11         | <b>-0.32</b> | -0.02   | -0.02       | -0.04        |
| Glu               | 229 | 0.297 | 0.19         | 0.10         | 0.14         | -0.07   | 0.03        | 0.04         |
| HbA <sub>1c</sub> | 229 | 0.314 | 0.14         | -0.05        | <b>0.23</b>  | -0.05   | 0.01        | 0.06         |
| TC                | 229 | 0.354 | <b>0.23</b>  | 0.12         | 0.18         | 0.01    | 0.07        | 0.01         |
| TG                | 229 | 0.453 | <b>0.27</b>  | -0.06        | <b>0.28</b>  | -0.04   | -0.05       | 0.04         |
| HDL-C             | 227 | 0.138 | 0.11         | 0.05         | -0.07        | 0.02    | 0.04        | -0.04        |
| LDL-C             | 228 | 0.333 | 0.18         | 0.11         | <b>0.21</b>  | 0.03    | 0.07        | -0.02        |
| nonHDL            | 228 | 0.368 | <b>0.20</b>  | 0.10         | <b>0.24</b>  | 0.02    | 0.06        | -0.01        |
| TC/HDL            | 229 | 0.316 | 0.11         | 0.04         | <b>0.26</b>  | 0.00    | 0.04        | 0.05         |
| HDL/LDL           | 229 | 0.279 | -0.10        | -0.06        | <b>-0.22</b> | -0.02   | -0.05       | -0.03        |
| CRP               | 227 | 0.399 | 0.12         | 0.03         | <b>0.34</b>  | 0.07    | -0.04       | -0.08        |
| IgG               | 229 | 0.229 | -0.11        | 0.09         | -0.14        | 0.01    | 0.01        | -0.08        |
| IgA               | 229 | 0.251 | 0.18         | 0.18         | -0.08        | -0.05   | -0.02       | -0.01        |
| IgM               | 227 | 0.247 | <b>-0.23</b> | 0.00         | -0.02        | -0.01   | 0.05        | -0.09        |
| C3                | 228 | 0.366 | 0.04         | 0.00         | <b>0.35</b>  | 0.00    | -0.03       | 0.02         |
| C4                | 228 | 0.314 | 0.15         | 0.10         | <b>0.20</b>  | -0.05   | 0.08        | 0.01         |

R=multiple correlation coefficient. Akan=dummy variable indicating ethnicity (Akan=1; nonAkan=0) Alcohol=habit of drinking alcohol (Yes=1; No=0); ExerLvl=days/week of regular exercise (0–7); HrStand=hours of standing/day. The width of bar in each cell represents partial correlation coefficient ( $r_p$ ) with negative value shown by red bar.  $|r_p| \geq 0.2$  was marked by bold font.


females. These findings are shown graphically for 12 representative analytes in Figure 2.

None of the analytes, including GGT or ALT, showed any significant association with drinking, obviously attributable to infrequent drinking habits of our volunteers: 13.2% (male: 15.6% female: 10.4%). The level of regular exercise or hours of standing per day was not significantly associated with any analyte. We did not include smoking habit in MRA because only three subjects were smokers. Using the dummy variable of Akan or not to examine the effects of ethnicity, only AG and IP showed

weak associations in both sexes: i.e., their RVs in Akan were lower than non-Akan.


## Standard deviation ratio (SDR) as a guide for partitioning RVs

The magnitude of between-sex differences is shown in Table 3 expressed as  $SDR_{sex}$  that was derived by two-level nested ANOVA with age as covariate.  $SDR_{sex} \geq 0.4$  was observed for



**Figure 1:** Sex and age-related changes of representative chemistry analytes.

RVs were partitioned by sex (male: M, female: F) and age-subgroups (~29, 30–39, 40–49, 50~). The box in the center of each scattergram indicates the mid 50% range of RVs, and its central vertical bar represents the median. The data size of each subgroup is shown at the right bottom of the age group labels. Because no secondary exclusion was done for RVs, the range of the scattergrams may not match to the RI, which is to be derived with inclusion of single mean  $\pm$  2.81 SD truncation step under the transformed scale.



**Figure 2:** Association of BMI with RVs of nutritional/inflammatory markers.

Associations of BMI (on x-axis) with RVs of 12 analytes (on y-axis) are shown separately for males (blue dots) and females (red dots) by 2D-scattergram. The least-square regression lines are drawn and Spearman's correlation coefficients are calculated for both sexes.

Cre, UA, ALT, Alb, AST, CK, DBil, TBil, Cl, GGT, IgM, C3, and Ca, in the descending order of magnitude. The direction of gender difference in RVs was all higher in males except for Cl, and IgM. For age related change,  $SDR_{age}$  specific for each gender was derived as  $SDR_{ageM}$  or  $SDR_{ageF}$  by one-way ANOVA. For males, only  $SDR_{ageM}$  for Alb and eGFR were significant, while for females,  $SDR_{ageF}$  were significant for Na, eGFR, Ca, TG, and ALP. From Supplementary Figure 1, the direction of changes is increase with age for all analytes except for Ca and Alb.

## Derivation of RIs

RIs were calculated in four ways by parametric (P) and nonparametric (NP) methods with/without application of

the LAVE method. The comparisons of RIs for all analytes are shown in Supplementary Figure 3. It was obvious that UL by NP method was biased to the higher side and its 90% CI was generally wider especially for analytes with skewed distribution such as ALT, CK, GGT, and CRP. Judged from BR of  $>0.375$  with/without LAVE shown in Supplementary Table 2, the LAVE procedure had a notable effect in lowering ULs for AST, ALT, GGT, TC, TG, nonHDL, LDL-C, TC/HDL, CRP in both sexes, UA and Cre in females, and CK and IgM in males.

The effect of excluding individuals with high BMI ( $\geq 30$  kg/m<sup>2</sup>) was examined for the analytes with high  $r_p$  by MRA as shown in Supplementary Table 3. Based on BR of  $>0.375$  as a significant effect of BMI restriction, we adopted the BMI-restricted RIs for UA, TC, LDL-C, and CRP for both sexes and, for nonHDL and TG for females only.

Table 3: SDRs representing between-sex, between-age differences.

|                  |     | 2-level ANOVA |             | One-way ANOVA |             |
|------------------|-----|---------------|-------------|---------------|-------------|
| Analyte          | N   | SDRsex        | SDRage      | SDRageM       | SDRageF     |
| TP               | 500 | 0.12          | 0.38        | 0.37          | 0.38        |
| Alb              | 500 | <b>0.62</b>   | <b>0.43</b> | <b>0.48</b>   | 0.36        |
| Glb              | 500 | 0.19          | 0.22        | 0.11          | 0.30        |
| TBil             | 499 | <b>0.58</b>   | 0.00        | 0.00          | 0.00        |
| DBil             | 498 | <b>0.59</b>   | 0.00        | 0.00          | 0.00        |
| UA               | 497 | <b>0.95</b>   | 0.28        | 0.16          | 0.39        |
| Urea             | 500 | 0.25          | 0.25        | 0.00          | 0.36        |
| Cre              | 500 | <b>1.15</b>   | 0.22        | 0.06          | 0.34        |
| eGFR             | 498 | 0.14          | <b>0.60</b> | <b>0.48</b>   | <b>0.69</b> |
| Na               | 498 | 0.00          | <b>0.54</b> | 0.19          | <b>0.82</b> |
| K                | 498 | 0.00          | 0.16        | 0.00          | 0.26        |
| Cl               | 500 | <b>0.56</b>   | 0.19        | 0.21          | 0.16        |
| TCO <sub>2</sub> | 500 | 0.33          | 0.34        | 0.31          | 0.37        |
| AG               | 500 | 0.00          | 0.20        | 0.27          | 0.00        |
| Ca               | 499 | <b>0.43</b>   | <b>0.41</b> | 0.36          | <b>0.45</b> |
| aCa              | 498 | 0.00          | 0.18        | 0.00          | 0.28        |
| Mg               | 500 | 0.00          | 0.19        | 0.09          | 0.27        |
| IP               | 497 | 0.24          | 0.00        | 0.00          | 0.00        |
| AST              | 499 | <b>0.61</b>   | 0.11        | 0.13          | 0.09        |
| ALT              | 497 | <b>0.67</b>   | 0.21        | 0.26          | 0.05        |

|         |     | 2-level ANOVA |        | One-way ANOVA |             |
|---------|-----|---------------|--------|---------------|-------------|
| Analyte | N   | SDRsex        | SDRage | SDRageM       | SDRageF     |
| LDH     | 499 | 0.00          | 0.00   | 0.00          | 0.07        |
| ALP     | 498 | 0.00          | 0.28   | 0.00          | <b>0.42</b> |
| GGT     | 496 | <b>0.54</b>   | 0.11   | 0.12          | 0.11        |
| CK      | 498 | <b>0.59</b>   | 0.19   | 0.14          | 0.25        |
| AMY     | 497 | 0.29          | 0.18   | 0.00          | 0.30        |
| Glu     | 496 | 0.14          | 0.22   | 0.20          | 0.24        |
| HbA1c   | 500 | 0.00          | 0.28   | 0.24          | 0.32        |
| TC      | 500 | 0.00          | 0.27   | 0.14          | 0.36        |
| TG      | 500 | 0.22          | 0.36   | 0.30          | <b>0.43</b> |
| HDL-C   | 498 | 0.31          | 0.00   | 0.00          | 0.00        |
| LDL-C   | 499 | 0.00          | 0.21   | 0.13          | 0.29        |
| NonHDL  | 499 | 0.00          | 0.25   | 0.18          | 0.33        |
| TC/HDL  | 500 | 0.22          | 0.19   | 0.18          | 0.21        |
| HDL/LDL | 500 | 0.15          | 0.17   | 0.17          | 0.17        |
| CRP     | 497 | 0.27          | 0.23   | 0.24          | 0.20        |
| IgG     | 499 | 0.00          | 0.08   | 0.04          | 0.11        |
| IgA     | 500 | 0.00          | 0.21   | 0.26          | 0.16        |
| IgM     | 496 | <b>0.49</b>   | 0.16   | 0.00          | 0.24        |
| C3      | 499 | <b>0.49</b>   | 0.13   | 0.15          | 0.10        |
| C4      | 497 | 0.38          | 0.24   | 0.25          | 0.23        |

The value of  $\text{SDR} \geq 0.4$  was marked by bold letter, and  $\text{SDR} \geq 0.5$  was highlighted by a gray shade. SDRage was computed for males (M) and females (F), separately as SDRageM and SDRageF.

In Figure 3, we illustrated the effect of LAVE procedure and/or BMI restriction for four representative analytes: ALT, GGT, LDL-C and CRP. Effect of LAVE in lowering UL of the RI was observed more or less in all four analytes, while additional lowering of UL by BMI restriction was noted only in LDL-C and CRP. In other words, for RVs of ALT and GGT, the LAVE procedure had nearly the same effect as the BMI restriction.

In Table 4, a list of RIs adopted for all analytes are presented. For the selection of RIs with/without partition by sex and age, we principally used  $\text{SDR}_{\text{sex}}$  and  $\text{SDR}_{\text{age}}$ , but we also considered the bias at the RI limits ( $B_{\text{LL}}$  and  $B_{\text{UL}}$ ), which are presented in Supplementary Table 2. For partitioning RVs by sex based on  $\text{SDR}_{\text{sex}} \geq 0.4$ , the analytes selected were as noted above. However, actual between-sex difference at RI limits for Cl and Ca was less than three reporting units, and thus their RIs were determined without partition by sex. Whereas RVs for eGFR, IP, LDH, ALP, AMY, nonHDL, TG, TC/HDL, CRP and C4 recorded  $\text{SDR}_{\text{sex}} < 0.4$ , yet, their actual between-sex differences at LL or UL expressed as  $B_{\text{LL}}$  or  $B_{\text{UL}}$  were high ( $> 0.57$ ), and thus their RIs were determined for each sex. For partitioning by age,  $\text{SDR}_{\text{age}} \geq 0.4$


was noted, in females for Na, Ca, ALP, and TG, in males for Alb, in both sexes for eGFR (Supplementary Table 3). However, for Alb, Na, and Ca, actual differences at RI limits after partition at 45 years of age were small (3 g/L, 2 mmol/L, 0.06 mmol/L, respectively), and thus no partitioning was done (Supplementary Table 4). For TG in females, despite  $\text{SDR}_{\text{age}} > 0.4$ ,  $B_{\text{UL}}$  after partition by age was small ( $< 0.57$ ). Hence, the RIs was not partitioned by age.

### Standardization of RIs

Comparisons of our test results for 50 panel sera with assigned values are shown in Supplementary Figure 2. The need for recalibrating the derived RI (LL~UL) was assessed by computing adjusted RI (LLa~ULa) by using major axis regression line coefficients [6] shown in the Figure, and by calculating  $B_{\text{LL}}$  and  $B_{\text{UL}}$ .

By regarding  $B_{\text{R}} > 0.375$  as exceeding allowable analytical bias, recalibration of RIs was performed for Alb, Ca, IP, AST, ALT, LDH, ALP, and HDL-C, but not for Na and





**Figure 3:** Effect of LAVE and BMI restriction on RIs of nutritional markers.

RIs of four representative nutritional markers were calculated for each sex in four ways: (1) using all RVs [1: All (2 + 3)], (2) using RVs that remained after latent abnormal values exclusion (LAVE) procedure [2: LAV Ex], (4) using RVs from individuals with BMI<30 kg/m<sup>2</sup> [4: BMI<30], (5) using RVs that remained after BMI restriction plus LAVE [5: 4 & LAV Ex]. The RI determined for each category of RVs is shown as rectangular region drawn over the scattergram. The scattergram (3) in the third row of each sex represents the subset of RVs that were excluded by the LAVE procedure [3: LAV]. Hence the scattergram (1) is broken down into scattergrams (2) and (3). In applying LAVE, the following mutually associated reference tests were used for identifying individuals with latent abnormal values: Alb, Glb, UA, Glu, AST, GGT, CK, LDH, TC, nonHDL, TG, and CRP. It is of note that, there seems to exist excessive number of points outside the RI overlaid, but, in the derivation of the RI, values outside mean  $\pm 2.81$  SD were truncated once.

CI because of high imprecision of slope  $b$  [ $CV(b) > 11\%$ ] of the regression line as described elsewhere [6].

## Discussion

In this study to establish RIs suitable for Ghana, sources of variation analyses of RVs were performed using MRA and ANOVAs. Sex, age, and BMI were major SVs requiring consideration in deriving RIs, while ethnicity was not relevant in any analyte except AG and IP, which were marginally lower among Akan who constituted 40% of the study subjects, but below the level requiring separate RIs.

Both smoking and drinking did not have any impact as they were infrequent among the volunteers.

In judging the need for partitioning RVs, we primarily relied on SDR by using 0.4 as the cut-off threshold, which was empirically derived based on traditional practice of setting sex-specific RIs in most clinical laboratories [4]. As a secondary criterion for partitioning, we relied on bias ratio (BR) or between-group difference at RI limits (e.g.,  $UL_1 - UL_2$ ) divided by  $SD_{RI}$ . To make threshold of BR aligned to SDR with common denominator ( $SD_{RI}$ ), we multiplied  $SDR = 0.4$  by  $\sqrt{2}$  to obtain its threshold of  $0.4 \times \sqrt{2} = 0.57$ : i.e., absolute difference (bias) of two values ( $x_1$  and  $x_2$ ), or  $|x_1 - x_2|$ , is  $\sqrt{2}$  times larger than SD of the two values. It is of

Table 4: List of RIs after recalibration.

|                  |                            |     |     |       |      | Reference Interval by parametric method |             |       |      |      |             |             |
|------------------|----------------------------|-----|-----|-------|------|---|-------------|-------|------|------|-------------|-------------|
| Item             | unit                       | Sex | BMI | Age   | LAVE | n                                       | 90%CI of LL | LL    | Me   | UL   | 90%CI of UL |             |
| TP               | g/L                        | MF  | All | 18-70 | (-)  | 499                                     | 64.5        | 65.7  | 65   | 74   | 84          | 82.8 84.3   |
| Alb              | g/L                        | MF  | All | 18-70 | (-)  | 501                                     | 37.2        | 38.3  | 38   | 44   | 49          | 49.0 49.8   |
| Glb              | g/L                        | MF  | All | 18-70 | (-)  | 499                                     | 23.0        | 24.4  | 24   | 31   | 40          | 38.9 40.4   |
| TBil             | μmol/L                     | M   | All | 18-70 | (-)  | 267                                     | 6.3         | 7.6   | 7    | 14   | 36          | 32.6 38.6   |
|                  |                            | F   | All | 18-70 | (-)  | 229                                     | 4.9         | 5.9   | 5    | 10   | 24          | 21.0 26.6   |
| DBil             | μmol/L                     | M   | All | 18-70 | (-)  | 267                                     | 1.2         | 1.5   | 1.4  | 2.8  | 7.0         | 6.3 7.7     |
|                  |                            | F   | All | 18-70 | (-)  | 229                                     | 0.8         | 1.1   | 1.0  | 1.9  | 4.8         | 4.2 5.4     |
| UA               | μmol/L                     | M   | <30 | 18-70 | (-)  | 247                                     | 221         | 237   | 229  | 331  | 467         | 452 482     |
|                  |                            | F   | <30 | 18-70 | (+)  | 132                                     | 131         | 164   | 147  | 239  | 347         | 330 365     |
| Urea             | mmol/L                     | MF  | All | 18-70 | (-)  | 500                                     | 2.08        | 2.27  | 2.2  | 3.5  | 5.7         | 5.49 5.97   |
| Cre              | μmol/L                     | M   | All | 18-70 | (-)  | 269                                     | 55          | 61    | 58   | 80   | 109         | 104 113     |
|                  |                            | F   | All | 18-70 | (+)  | 174                                     | 38          | 43    | 40   | 59   | 82          | 78 85       |
| eGFR             | ml/min /1.73m <sup>2</sup> | MF  | All | 18-44 | (-)  | 302                                     | 85          | 97    | 91   | 133  | 200         | 193 207     |
|                  |                            | MF  | All | 45-70 | (-)  | 196                                     | 70          | 76    | 73   | 109  | 167         | 158 176     |
| Na               | mmol/L                     | MF  | All | 18-70 | (-)  | 497                                     | 135.3       | 135.9 | 136  | 139  | 143         | 142.6 143.7 |
| K                | mmol/L                     | MF  | All | 18-70 | (-)  | 498                                     | 3.39        | 3.52  | 3.5  | 4.2  | 5.0         | 4.88 5.07   |
| Cl               | mmol/L                     | MF  | All | 18-70 | (-)  | 500                                     | 98.1        | 99.0  | 99   | 103  | 108         | 107.3 108.3 |
| TCO <sub>2</sub> | mmol/L                     | MF  | All | 18-70 | (-)  | 501                                     | 17.6        | 18.4  | 18.0 | 22.8 | 27.3        | 26.9 27.7   |
| AG               | mmol/L                     | MF  | All | 18-70 | (-)  | 501                                     | 8.1         | 8.8   | 8.5  | 12.9 | 21.1        | 20.4 21.8   |
| Ca               | mmol/L                     | MF  | All | 18-70 | (-)  | 500                                     | 2.16        | 2.19  | 2.17 | 2.34 | 2.51        | 2.50 2.53   |
| aCa              | mmol/L                     | MF  | All | 18-70 | (-)  | 498                                     | 2.14        | 2.17  | 2.16 | 2.27 | 2.41        | 2.40 2.43   |
| Mg               | mmol/L                     | MF  | All | 18-70 | (-)  | 501                                     | 0.71        | 0.73  | 0.72 | 0.83 | 0.97        | 0.96 0.98   |
| IP               | mmol/L                     | M   | All | 18-70 | (-)  | 266                                     | 0.70        | 0.82  | 0.76 | 1.03 | 1.44        | 1.37 1.51   |
|                  |                            | F   | All | 18-70 | (-)  | 228                                     | 0.83        | 0.95  | 0.89 | 1.11 | 1.63        | 1.51 1.75   |
| AST              | U/L                        | M   | All | 18-70 | (+)  | 210                                     | 18.4        | 21.0  | 20   | 27   | 43          | 38.8 46.6   |
|                  |                            | F   | All | 18-70 | (+)  | 176                                     | 17.2        | 18.1  | 18   | 22   | 32          | 29.8 33.4   |
| ALT              | U/L                        | M   | All | 18-70 | (-)  | 264                                     | 8.5         | 10.0  | 9    | 21   | 57          | 51.0 61.8   |
|                  |                            | F   | All | 18-70 | (+)  | 176                                     | 6.2         | 7.4   | 7    | 13   | 27          | 24.9 30.1   |
| ALP              | U/L                        | M   | All | 18-70 | (-)  | 268                                     | 46          | 53    | 49   | 80   | 130         | 122 138     |
|                  |                            | F   | All | 18-44 | (-)  | 136                                     | 38          | 50    | 44   | 74   | 119         | 110 129     |
|                  |                            | F   | All | 45-70 | (-)  | 85                                      | 46          | 59    | 52   | 88   | 139         | 124 155     |
| GGT              | U/L                        | M   | All | 18-70 | (+)  | 209                                     | 14.6        | 19.2  | 17   | 33   | 87          | 71.3 103.3  |
|                  |                            | F   | All | 18-70 | (+)  | 176                                     | 11.3        | 12.9  | 13   | 23   | 47          | 43.6 52.4   |
| CK               | U/L                        | M   | All | 18-70 | (+)  | 211                                     | 76          | 111   | 94   | 207  | 518         | 433 604     |
|                  |                            | F   | All | 18-70 | (-)  | 227                                     | 41          | 64    | 52   | 139  | 300         | 257 343     |
| LDH              | U/L                        | M   | All | 18-70 | (-)  | 269                                     | 150         | 163   | 157  | 218  | 294         | 285 304     |
|                  |                            | F   | All | 18-70 | (-)  | 230                                     | 159         | 172   | 166  | 221  | 308         | 298 319     |
| AMY              | U/L                        | M   | All | 18-70 | (-)  | 268                                     | 42          | 55    | 48   | 101  | 181         | 166 196     |
|                  |                            | F   | All | 18-70 | (-)  | 228                                     | 40          | 53    | 46   | 85   | 162         | 149 175     |
| Glu              | 0.09                       | MF  | All | 18-70 | (-)  | 494                                     | 3.84        | 4.06  | 3.95 | 4.85 | 5.94        | 5.78 6.09   |
| HbA1c            | %                          | MF  | All | 18-70 | (-)  | 498                                     | 4.11        | 4.40  | 4.26 | 5.37 | 6.26        | 6.14 6.39   |
| TC               | mmol/L                     | MF  | <30 | 18-70 | (+)  | 331                                     | 3.25        | 3.69  | 3.47 | 5.02 | 7.10        | 6.85 7.36   |
| HDL-C            | mmol/L                     | MF  | All | 18-70 | (-)  | 498                                     | 0.87        | 0.97  | 0.92 | 1.41 | 2.18        | 2.12 2.25   |
| nonHDL           | mmol/L                     | M   | All | 18-70 | (+)  | 216                                     | 1.93        | 2.36  | 2.15 | 3.85 | 6.12        | 5.70 6.54   |
|                  |                            | F   | <30 | 18-70 | (+)  | 132                                     | 2.18        | 2.55  | 2.36 | 3.55 | 5.45        | 4.99 5.91   |
| TG               | mmol/L                     | M   | All | 18-70 | (+)  | 214                                     | 0.39        | 0.46  | 0.42 | 0.88 | 2.08        | 1.84 2.33   |
|                  |                            | F   | <30 | 18-70 | (+)  | 130                                     | 0.35        | 0.44  | 0.40 | 0.70 | 1.57        | 1.22 1.93   |
| LDL-C            | mmol/L                     | M   | <30 | 18-70 | (+)  | 208                                     | 1.87        | 2.09  | 1.97 | 3.40 | 5.15        | 4.97 5.29   |
|                  |                            | F   | <30 | 18-70 | (+)  | 127                                     | 2.06        | 2.24  | 2.14 | 3.21 | 4.70        | 4.48 4.98   |
| TC/HDL           |                            | M   | All | 18-70 | (+)  | 208                                     | 2.38        | 2.72  | 2.55 | 4.15 | 6.58        | 6.21 6.96   |
|                  |                            | F   | All | 18-70 | (+)  | 173                                     | 2.47        | 2.79  | 2.63 | 3.68 | 5.85        | 5.40 6.31   |
| HDL/LDL          |                            | MF  | All | 18-70 | (-)  | 497                                     | 0.18        | 0.21  | 0.20 | 0.38 | 0.74        | 0.70 0.78   |
| CRP              | mg/L                       | M   | <30 | 18-70 | (+)  | 194                                     | 0.13        | 0.21  | 0.17 | 0.83 | 4.93        | 3.76 6.07   |
|                  |                            | F   | <30 | 18-70 | (+)  | 136                                     | 0.42        | 0.49  | 0.44 | 1.16 | 6.75        | 4.75 7.86   |
| IgG              | mg/dL                      | MF  | All | 18-70 | (-)  | 498                                     | 1133        | 1193  | 1163 | 1589 | 2170        | 2123 2217   |
| IgA              | mg/dL                      | MF  | All | 18-70 | (-)  | 500                                     | 106         | 122   | 114  | 225  | 417         | 387 446     |
| IgM              | mg/dL                      | M   | All | 18-70 | (+)  | 207                                     | 34          | 44    | 39   | 86   | 181         | 158 204     |
|                  |                            | F   | All | 18-70 | (-)  | 228                                     | 46          | 57    | 51   | 119  | 269         | 249 289     |
| C3               | mg/dL                      | M   | All | 18-70 | (-)  | 270                                     | 79          | 85    | 82   | 113  | 164         | 158 169     |
|                  |                            | F   | All | 18-70 | (-)  | 230                                     | 90          | 98    | 94   | 129  | 170         | 166 175     |
| C4               | mg/dL                      | M   | All | 18-70 | (-)  | 268                                     | 13          | 16    | 15   | 28   | 46          | 44 48       |
|                  |                            | F   | All | 18-70 | (-)  | 230                                     | 15          | 19    | 17   | 33   | 53          | 49 57       |

M=male; F=female; MF=M+F; LL=lower limit; Me=mid-point; UL=upper limit; CI=confidence interval. LAVE=latent abnormal values exclusion. (-) LAVE denoted with color light green shows that the LAVE method was not applied. (+) LAVE with a green color shows LAVE method was used. Yellow color code depicts the reference interval derived for all age and Bmi. Violet color code represents both male and female (M + F) reference interval. light blue color shows male reference interval. pink shows female reference interval.

note that, in judging the bias in LL or UL caused by LAVE or BMI restriction, we adopted the distinct threshold of 0.375 that corresponds to the limit of allowable analytical bias.

Our findings of high between-sex differences ( $SDR_{sex}$ ) observed in 12 analytes shown in Table 3 were all consistent with most previous studies [2, 3, 20, 21]. A notable exception was HDL-C, whose  $SDR_{sex}$  and BRs were not large enough to require sex-partition. This lack of gender-difference in Ghanaian HDL-C may be attributable to its decrease by prevalent obesity observed in females, with an opposing increase in males due to higher physical activity.

With respect to age-related changes,  $r_p$  for age (by MRA) and  $SDR_{age}$  (by ANOVA), the RVs of Alb and eGFR showed appreciable lowering with age in both sexes. While age-related increase was found for Na, Ca, TG, and ALP in females, however actual differences in RIs partitioned at 45 years were rather small for Alb, Na, and Ca (less than three reporting units) and for TG ( $BR_{UL} < 0.57$ ), therefore, only ALP of females and eGFR was partitioned at 45 years of age. This finding of ALP in females is consistent with other reports [3, 20].

BMI was a prominent SV for many analytes in our study judged from  $r_p$  for BMI and 2D-scattergram shown in Figure 2. BMI-related increase of RVs with  $r_p > 0.2$  has been noted in many nutritional and inflammatory markers in both sexes and indeed is consistent with what was reported in the interim report of the global multicentre study and other studies [12, 22, 23]. Also, BMI was inversely associated with HDL-C and AMY in both sexes; a finding consistent with several reports [22]. Although low HDL-C levels are well known to be associated with cardiovascular disorders, low serum AMY is also associated with obesity and risk of diabetes mellitus [24]. Hence, in this study, we excluded individuals with  $BMI \geq 30 \text{ kg/m}^2$  which is regarded as excessively obese and constitutes 16.6% of the volunteers (male, 8.1%; female, 26.4%). The exclusion procedure resulted in significant lowering of ULs ( $BR_{UL}$ ) for UA, TC, LDL-C, and CRP in both sexes, and for TG and nonHDL in females (Supplementary Table 3) while, in other nutritional markers, the LAVE procedure effectively reduced the influence of high BMI on RIs.

In comparison to the standardized RIs reported from nine countries that collaborated in the C-RIDL global study, we identified features that were unique to the Ghanaian RIs as partly shown in Figure 4. The most conspicuous ones are a higher-side shift of RIs for TBil, LDH, CK and AMY. Even though high levels of these analytes among

African population have been reported [8–10, 25, 26], the level of CK, TBil and AMY were even higher among Ghanaian population. The higher AMY might be attributable to high carbohydrate consumption in Ghana besides genetic factors [25, 27]. Remarkably, the RIs of TC and LDL-C were also shifted to higher levels in contrast to other countries except for Russia, and similarly for HDL-C except for the RIs of Japan. Hence, these features must be considered in interpreting lipid profiles in the management of atherosclerotic diseases. These between-country variations may be attributed to differences in lifestyle and/or genetic factor among the study population [3].


The LAVE procedure effectively narrowed RIs especially for hepatic and lipid markers as reported elsewhere [2, 17, 21], which emphasizes the importance of secondary exclusions in deriving RIs for chemistry analytes that frequently are observed to be abnormal among healthy individuals.

## Limitations

Our volunteers largely represented the urban population, whose socioeconomic status, nutrition and lifestyles are likely to be different from the rural population. Hence some of derived RIs may differ in the rural setting. Another limitation was that we relied on self-reporting of health status and might have inevitably included individuals with latent, metabolic or inflammatory disorders. However, the application of the LAVE method and BMI restriction, if appropriate, seem to have coped with those conditions or in compliance to the sampling requirements.

## Conclusions

This study demonstrated that sex, age, and BMI were critical factors which required objective assessments in deriving country specific RIs. The application of LAVE and BMI restriction methods were found to be essential in reducing the influence of abnormal values frequently observed in chemistry test results among healthy subjects. The availability of value-assigned serum panel allowed us to ensure the RIs were standardized and furthermore able to identify Ghanaian features of RIs that were unique in comparison to those of other collaborating countries.



**Figure 4:** RIs of 10 countries in collaboration were compared for six analytes with Ghanaian specific features. RIs of 10 countries that collaborated in the global study were compared by bar-chart for six representative analytes that exhibited features specific for Ghanaian and/or Africans. The blue, pink, and purple background shades denote the RIs of Ghana derived for male (M), female (F), and M + F, respectively. Please note that all the RIs were made comparable through standardization based on the value-assigned serum panel measured in common. ZAF denotes RIs determined selectively from African in South Africa [28]. TUR=Turkey [21]; JPN=Japan [29]; CHN=China [3]; SAU=Saudi [2], RUS=Russia [30]; IND=India [31]; KEN=Kenya [26]; EGY=Egypt [32].

**Research funding:** The main financial support for this research was provided by Medlab Ghana Limited, Synlab, Germany, and by the research fund of Prof. K. Ichihara acquired from Japan Society of Promotion of Science (#16H02771).

**Author contributions:** KI, RE, RK, PA-K, JF, JA-M and SAB contributed to the conception and designed of the project. Recruitment of volunteers, sample collection and measurements were conducted by SAB, RK, PA-K, JF, and JA-M. Data processing and statistical analyses were performed by KI and SAB. The initial draft of the manuscript was written by SAB, KI, and JF, with critical review by JA-M, RE, PA-K and RK. All authors discussed the results and contributed to the final manuscript write up.

**Competing interests:** Authors states no conflict of interest.

**Informed consent:** Written consents were obtained from all volunteers. Participants' confidentiality was maintained at all times.

**Ethical approval:** The study protocol conforming to the Declaration of Helsinki was approved by the Ethical Review Committee of the College of Health Sciences, University of Ghana (CHS-Et/M.8-P4.14/2016–2017).

## References

1. Concordet D, Geffré A, Braun J-P, Trumel C. A new approach for the determination of reference intervals from hospital-based data. *Clin Chim Acta* 2009;405:43–8.
2. Borai A, Ichihara K, Al Masaoud A, Tamimi W, Bahijri S, Armbuster D, et al. Establishment of reference intervals of clinical chemistry analytes for the adult population in Saudi Arabia: a study conducted as a part of the IFCC global study on reference values. *Clin Chem Lab Med* 2016;54:843–55.
3. Xia L, Chen M, Liu M, Tao Z, Li S, Wang L, et al. Nationwide multicenter reference interval study for 28 common biochemical analytes in China. *Medicine* 2016;95:e2915.
4. Ichihara K, Itoh Y, Lam CW, Poon PM, Kim J-H, Kyono H, et al. Sources of variation of commonly measured serum analytes in 6 Asian cities and consideration of common reference intervals. *Clin Chem* 2008;54:356–65.
5. Ichihara K, Ceriotti F, Kazuo M, Huang YY, Shimizu Y, Suzuki H, et al. The Asian project for collaborative derivation of reference intervals: (2) results of non-standardized analytes and transference of reference intervals to the participating laboratories on the basis of cross-comparison of test results. *Clin Chem Lab Med* 2013;51:1443–57.
6. Ichihara K. Statistical considerations for harmonization of the global multicenter study on reference values. *Clin Chim Acta* 2014;432:108–18.
7. Ozarda Y, Ichihara K, Barth JH, Klee G. Protocol and standard operating procedures for common use in a worldwide multicenter study on reference values. *Clin Chem Lab Med* 2013;51:1027–40.
8. Miri-Dashe T, Osawe S, Tokdung M, Daniel N, Choji RP, Mamman I, et al. Comprehensive reference ranges for hematology and clinical chemistry laboratory parameters derived from normal Nigerian adults. *PLoS One* 2014;9:e93919.
9. Karita E, Ketter N, Price MA, Kayitenkore K, Kaleebu P, Nanvubya A, et al. CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. *PLoS One* 2009;4:e4401.
10. Kibaya RS, Bautista CT, Sawe FK, Shaffer DN, Saterren WB, Scott PT, et al. Reference ranges for the clinical laboratory derived from a rural population in Kericho, Kenya. *PLoS One* 2008;3:e3327.
11. Koram KA, Addae MM, Ocran JC, Adu-amankwah S, Rogers WO, Nkrumah FK. Population based reference intervals for common blood haematological and biochemical parameters in the Akuapem north district. *Ghana Med J* 2007;41. <https://doi.org/10.4314/gmj.v41i4.55284>.
12. Ichihara K, Ozarda Y, Barth JH, Klee G, Qiu L, Erasmus R, et al. A global multicenter study on reference values: 1. Assessment of methods for derivation and comparison of reference intervals. *Clin Chim Acta* 2017;467:70–82.
13. Shimizu Y, Ichihara K, Kouguchi K. Time required for resetting postural effects on serum constituents in healthy individuals. *Clin Chim Acta* 2017;472:131–5.
14. Plantinga L, Lee K, Inker LA, Saran R, Yee J, Gillespie B, et al. Association of sleep-related problems with CKD in the United States, 2005–2008. *Am J Kidney Dis* 2011;58:554–64.
15. Cohen J. A power primer. *J Psychol Bull* 1992;112:155.
16. Fraser C, Hyltoft Petersen P, Ricos C, Haeckel R. Quality specifications. Biological variation: from principles to practice. Washington, DC: AACC Press; 2001:29–66 pp.
17. Ichihara K, Boyd JC. An appraisal of statistical procedures used in derivation of reference intervals. *Clin Chem Lab Med* 2010;48:1537–51.
18. Bawua A, Ichihara K, Keatley R, Arko-Mensah J, Dei-Adomakoh Y, Ayeh-Kumi PF, et al. Establishing Ghanaian adult reference intervals for hematological parameters controlling for latent anemia and inflammation. *Int J Lab Hematol* 2020;42:705–17.
19. Asare EV, Wilson I, Benneh-Akwasi Kuma AA, Dei-Adomakoh Y, Sey F, Olayemi E, et al. Burden of sickle cell disease in Ghana: the Korle-Bu experience. *Adv Hematol* 2018;2:6161270.
20. Yamakado M, Ichihara K, Matsumoto Y, Ishikawa Y, Kato K, Komatsubara Y, et al. Derivation of gender and age-specific reference intervals from fully normal Japanese individuals and the implications for health screening. *Clin Chim Acta* 2015;447:105–14.
21. Ozarda Y, Ichihara K, Aslan D, Aybek H, Ari Z, Taneli F, et al. A multicenter nationwide reference intervals study for common biochemical analytes in Turkey using Abbott analyzers. *Clin Chem Lab Med* 2014;52:1823–33.
22. Shamai L, Lurix E, Shen M, Novaro GM, Szomstein S, Rosenthal R, et al. Association of body mass index and lipid profiles: evaluation of a broad spectrum of body mass index patients including the morbidly obese. *Obes Surg* 2011;21:42–7.
23. Abd Ali ZAU, Al-Zaidi MS. The association between body mass index, lipid profile and serum estradiol levels in a sample of Iraqi diabetic premenopausal women. *Oman Med J* 2011;26:263.
24. Dias JP, Schrack JA, Shardell MD, Egan JM, Studenski S. Association of abdominal fat with serum amylase in an older cohort: the Baltimore Longitudinal Study of Aging. *Diabetes Res Clin Pract* 2016;116:212–7.



25. Brewster LM, Coronel CM, Sluiter W, Clark JF, Van Montfrans GA. Ethnic differences in tissue creatine kinase activity: an observational study. *PLoS One* 2012;7:e32471.
26. Omuse G, Ichihara K, Maina D, Hoffman M, Kagotho E, Kanyua A, et al. Determination of reference intervals for common chemistry and immunoassay tests for Kenyan adults based on an internationally harmonized protocol and up-to-date statistical methods. *PLoS One* 2020;15:e0235234.
27. Neal RC, Ferdinand KC, Yčas J, Miller E. Relationship of ethnic origin, gender, and age to blood creatine kinase levels. *Am J Med* 2009;122:73–8.
28. Smit FC, Ichihara K, George J, Blanco-Blanco E, Hoffmann M, Erasmus RT, et al. Establishment of reference intervals of biochemical analytes for South African adults: a study conducted as part of the IFCC global multicentre study on reference values. *Med Lab Sci Technol South Africa* 2021;3:8–23.
29. Ichihara K, Yamamoto Y, Hotta T, Hosogaya S, Miyachi H, Itoh Y, et al. Collaborative derivation of reference intervals for major clinical laboratory tests in Japan. *Ann Clin Biochem* 2016;53: 347–56.
30. Evgina S, Ichihara K, Ruzhanskaya A, Skibo I, Vybornova N, Vasiliev A, et al. Establishing reference intervals for major biochemical analytes for the Russian population: a research conducted as a part of the IFCC global study on reference values. *Clin Biochem* 2020;81:47–58.
31. Shah SAV, Ichihara K, Dherai AJ, Ashavaid TF. Reference intervals for 33 biochemical analytes in healthy Indian population: C-RIDL IFCC initiative. *Clin Chem Lab Med* 2018;56:2093–103.
32. Baz H, Ichihara K, Selim M, Awad A, Aglan S, Ramadan D, et al. Establishment of reference intervals of clinical chemistry analytes for the adult population in Egypt. *PLoS One*. 2021;16: e0236772.

---

**Supplementary Material:** The online version of this article offers supplementary material (<https://doi.org/10.1515/cclm-2022-0293>).